0 results available. Select is focused ,type to refine list, press Down to open the menu,
Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, and internationally. It operates ...
The following section summarizes insights on Zydus Lifesciences Ltd's P/E Ratio (Fwd):
We've identified the following companies as similar to Zydus Lifesciences Ltd because they operate in a related industry or sector. We also considered size, growth, and various financial metrics to narrow down the list to the ones listed below.
To view the full list of supported financial metrics please see Complete Metrics Listing.
Metrics similar to P/E Ratio (Fwd) in the valuation category include:
Indicates the multiple of forward earnings that stock investors are willing to pay for one share of the firm.
Forward Price-to-Earnings ratio, Forward P/E Multiple, or Forward P/E Ratio is valuation multiple that is defined as:
P/E Ratio = Market Capitalization / Forecast Net Income
or, using per-share numbers:
P/E Ratio = Stock Price / Forecast Earnings Per Share (EPS)
Applying this formula, Zydus Lifesciences’s P/E Ratio (Fwd) is calculated below:
Market Capitalization [ 893.6 B ]
(/) Forecast Net Income [ 46.6 B ]
(=) P/E Ratio (Fwd) [ 19.2x ]
P/E Ratio indicates the multiple of earnings investors are willing to pay for one share of the company. PE Multiples are widely used in practice even though they have significant pitfalls.
Since Earnings Per Share (EPS), defined as Forecast Net Income / Shares Outstanding, uses a Forecast Net Income in the calculation, P/E multiples are not always reliable for benchmarking companies with negative earnings or debt.
One reason why P/E ratios can be unreliable is because the ratio assumes a company’s equity has value. In practice, a company’s total Firm Value may be less than the debt on its Balance Sheet, with no value allocatable to the common equity. P/E ratios also do not adjust for differences in capital structure between companies. P/E conundrum by Khan Academy does a great job of explaining these pitfalls.
The tables below summarizes the trend in Zydus Lifesciences’s market capitalization over the next five years:
| Date | Market Cap | Earnings | P/E Ratio |
|---|---|---|---|
| 2025-03-31 | 893.6 B | 46.6 B | 19.2x |
| 2026-03-31 | 893.6 B | 45.5 B | 19.6x |
| 2027-03-31 | 893.6 B | 42.895 B | 20.8x |
| 2028-03-31 | 893.6 B | 42.933 B | 20.8x |
| 2029-03-31 | 893.6 B | 44.436 B | 20.1x |
The chart above depicts the distribution of p/e ratio (fwd) for companies operating in the Healthcare sector in the Developing economic region. Over 1,040 companies were considered in this analysis, and 1,001 had meaningful values. The average p/e ratio (fwd) of companies in the sector is 24.5x with a standard deviation of 41.2x.
Zydus Lifesciences Ltd's P/E Ratio (Fwd) of 19.2x ranks in the 54.2% percentile for the sector. The following table provides additional summary stats:
| Economic Risk Region | Developing |
| Total Constituents | 1,043 |
| Included Constituents | 1,001 |
| Min | -123.2x |
| Max | 290.9x |
| Median | 17.7x |
| Mean | 24.5x |
| Standard Deviation | 41.2x |
You can find companies with similar p/e ratio (fwd) using this stock screener.